Bio-Path Holdings, Inc. (NASDAQ:BPTH) Sees Large Increase in Short Interest

Bio-Path Holdings, Inc. (NASDAQ:BPTH) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 250,000 shares, an increase of 189.4% from the December 15th total of 86,400 shares. Approximately 5.8% of the company’s stock are sold short. Based on an average daily volume of 3,070,000 shares, the days-to-cover ratio is currently 0.1 days.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on shares of Bio-Path in a research report on Saturday. They set a “sell” rating for the company.

Hedge Funds Weigh In On Bio-Path

An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC purchased a new position in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned approximately 4.66% of Bio-Path at the end of the most recent reporting period. 5.74% of the stock is owned by hedge funds and other institutional investors.

Bio-Path Price Performance

NASDAQ BPTH traded up $0.01 on Wednesday, reaching $0.85. The stock had a trading volume of 135,955 shares, compared to its average volume of 272,128. The business’s 50-day moving average price is $0.90 and its 200 day moving average price is $1.15. Bio-Path has a 12-month low of $0.59 and a 12-month high of $10.78.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.